Translational lung cancer research最新文献

{"title":"Enhancing the precision of auxiliary diagnosis for lung cancer through use of <i>SHOX2</i> and <i>RASSF1A</i> methylation status in lung biopsy and lymph node biopsy specimens.","authors":"Ping Gu, Yue Wang, Chunlei Shi, Yuqing Chen, Jialin Qian, Yanjie Niu, Hai Zhang, Yunxia Bao, Bin She, Xiaosha Ren, Iyare Izevbaye, Baohui Han, Hua Zhong, Yu Dong","doi":"10.21037/tlcr-2024-1082","DOIUrl":"https://doi.org/10.21037/tlcr-2024-1082","url":null,"abstract":"<p><strong>Background: </strong>Exfoliated cells in biopsy fluid are commonly utilized for cytological testing to complement histological examination. Nevertheless, the sensitivity of cytological testing is relatively low. Therefore, there is an urgent need to identify more sensitive biomarkers that can substitute for cytology and improve the overall diagnostic accuracy of lung cancer biopsies. The study aims to find biomarkers with greater sensitivity to replace cytology and enhance the overall diagnostic accuracy of lung cancer biopsies by evaluating the complementary roles of cytology and methylation in relation to histology.</p><p><strong>Methods: </strong>A cohort of 173 patients, including 127 individuals diagnosed with lung cancer and 46 individuals with benign lesions, was successively recruited from Shanghai Chest Hospital. These patients underwent cell smear, ThinPrep cytologic test (TCT), methylation analysis, and histological examination to assess the complementary roles of cytology and methylation in relation to histology could be evaluated.</p><p><strong>Results: </strong>The cutoff values of <i>SHOX2</i> and <i>RASSF1A</i>, as determined by the receiver operating characteristic (ROC) curve and scatter plot, were 9 and 12, respectively. The combination of <i>SHOX2</i> and <i>RASSF1A</i> (LungMe) yielded areas under the curve (AUCs) of 0.967 and 0.999 in lung biopsy and lymph node biopsy liquids, respectively. The sensitivity and specificity of LungMe were 95.3% (121/127) and 97.8% (45/46), respectively. The combination of cytology and histology in the diagnosis of lung cancer did not lead to an increase in diagnostic sensitivity or negative predictive value (NPV), while the combination of LungMe methylation and histology achieved a diagnostic sensitivity and NPV of 100%. The sensitivity of cytology was influenced by the biopsy method, but methylation effectively supplemented cytology in the diagnosis of lung cancer, with a combined diagnostic efficiency of 87.5% to 100%. Furthermore, positive methylation was identified in 87.5% of patients with negative cytology results from lung biopsy and in 100% of patients with negative cytology results in lymph node biopsy. Among samples tested as histologically negative, five cases were observed in which the methylation tests were positive. Among them, four cases were confirmed to be malignant after a second biopsy, surgery, or clinical follow-up, with one case determination pending further evaluation.</p><p><strong>Conclusions: </strong>The findings suggest that LungMe methylation could replace cytology as an adjunctive diagnostic tool for histology. Moreover, a positive methylation test result could indicate a potential malignancy, necessitating further confirmation by the hospital and thereby reducing the likelihood of missed diagnoses.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 3","pages":"897-911"},"PeriodicalIF":4.0,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12000937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Will \"Sun\"-WUKONG, the monkey king, conquer EGFR exon 20 insertion mutation positive non-small cell lung cancer?","authors":"Molly Li, Ross A Soo","doi":"10.21037/tlcr-24-854","DOIUrl":"10.21037/tlcr-24-854","url":null,"abstract":"","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 2","pages":"323-327"},"PeriodicalIF":4.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of metastasis and treatment patterns among different histopathologic types of lung cancer: analysis of 6 years of nationwide lung cancer cohort data in Korea.","authors":"Jeong Uk Lim, Kyu Yean Kim, Ho Cheol Kim, Tae-Jung Kim, Hong Kwan Kim, Mi Hyoung Moon, Kyongmin Sarah Beck, Yang Gun Suh, Chang Hoon Song, Jin Seok Ahn, Jeong Eun Lee, Jae Hyun Jeon, Chi Young Jung, Jeong Su Cho, Yoo Duk Choi, Seung Sik Hwang, Young Sik Park, Soon Ho Yoon, Joon Young Choi, Chang-Min Choi, Seung Hun Jang","doi":"10.21037/tlcr-24-770","DOIUrl":"10.21037/tlcr-24-770","url":null,"abstract":"<p><strong>Background: </strong>Personalized management of stage IV lung cancer requires a deeper understanding of metastatic patterns and the potential benefits of localized treatments for each histologic type. This study aims to identify patterns of both intrathoracic and extrathoracic metastases across various histologic types of lung cancer using a nationwide Korean lung cancer database.</p><p><strong>Methods: </strong>The study analyzed data from patients diagnosed with lung cancer between 2014 and 2019, sourced from the Korean Association of Lung Cancer Registry (KALC-R). Patients with stage IV lung cancer, indicated by M staging, were included to focus on metastatic patterns.</p><p><strong>Results: </strong>The cohort included 7,562 stage IV lung cancer patients, with adenocarcinoma being the most prevalent histologic type, comprising 49.22% of cases (3,722 patients). M stage categorization showed that 27.3% were M1a, 56.3% M1b, 15.7% M1c, and 0.6% unspecified. The adenosquamous type had the highest proportion of patients with metastases in three or more organs (42.9%). Metastases to the liver and bones were consistently associated with decreased survival across histologic types. In adenocarcinoma, strong associations were observed between extrathoracic metastatic sites, particularly between bone and liver [odds ratio (OR) =3.93] and liver and adrenal glands (OR =2.85). Multivariate analysis revealed that patients receiving radiotherapy to lung lesions had significantly better overall survival (OS) [hazard ratio (HR) =0.68; 95% confidence interval (CI): 0.60-0.78; P<0.001] compared to those who did not. Radiotherapy to extrathoracic metastases also significantly improved survival (HR =0.84; 95% CI: 0.77-0.93; P<0.001).</p><p><strong>Conclusions: </strong>Understanding metastasis patterns and treatment options specific to each lung cancer histologic type is essential for improving treatment strategies.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 2","pages":"363-384"},"PeriodicalIF":4.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung cancer organoids: a new strategy for precision medicine research.","authors":"Yuan Meng, Xinyi Shu, Jie Yang, Yangyueying Liang, Meiying Zhu, Xuerui Wang, Yue Li, Fanming Kong","doi":"10.21037/tlcr-24-921","DOIUrl":"10.21037/tlcr-24-921","url":null,"abstract":"<p><p>This article discusses new strategies for lung cancer organoids (LCOs) in precision medicine research. Precision medicine aims to identify and develop highly selective drugs targeted at specific disease markers for precise treatment. Given the genetic diversity among lung cancer cells, it is evident that different tumor cells may respond differently to various treatment regimens. LCOs can not only faithfully reproduce the pathological and genomic characteristics of samples, maintaining most variations, including driver gene mutations, but also preserve the cytological features of malignant tumor cells, showing a highly correlated in vitro drug screening response with the mutation spectrum in primary tumors. At this stage, several large-scale LCO biobanks have been established, providing ample sample resources for researchers. Based on this, the development of emerging technologies is expected to overcome limitations in the success rate, accuracy, and stability of the organoid culture process, significantly enhancing the level of precision medicine for lung cancer. This article mainly introduces the applications of LCO models in basic research, including the identification of drug targets, prediction of treatment efficacy, and overcoming drug resistance, assisting in the formulation of personalized treatment plans to improve treatment outcomes. Additionally, the article emphasizes the potential of cancer organoid co-culture models in the field of immunotherapy and their key role in advancing the evolution of precision medicine treatment strategies.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 2","pages":"575-590"},"PeriodicalIF":4.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy as salvage therapy and an adjunct to immunotherapy: exploring local and abscopal mechanisms to overcome immunotherapy resistance: a narrative review.","authors":"Yunxin Yang, Tong Liu, Song Mi, Xin Liu, Salma K Jabbour, Ning Liang, Guodong Deng, Pingping Hu, Jiandong Zhang","doi":"10.21037/tlcr-2025-57","DOIUrl":"10.21037/tlcr-2025-57","url":null,"abstract":"<p><strong>Background and objective: </strong>Immune checkpoint inhibitors (ICIs) have ushered in a new era of therapies and play a significant role in the clinical treatment of a variety of tumors. However, immune resistance has increasingly created a bottleneck in treatment, making the question of how to overcome drug resistance an urgent issue to address. In this article, the mechanism of drug resistance is briefly described with a focus on how radiotherapy (RT) acts on the immune system to reverse immunotherapy failure. Combinations of existing treatment modalities need to be optimized to overcome resistance problems. Research has shown that some RT modalities reverse immune resistance or enhance efficacy when used in combination, which shows some value for immune resistance and is worthy of in-depth research.</p><p><strong>Methods: </strong>In this review, we searched the literature published from 2000 to 2023 surrounding immunotherapy, RT and cancer.</p><p><strong>Key content and findings: </strong>Based on the immune effects and immunosuppressive effects induced by RT, this review examined the preclinical rationales of RT and its clinical results. The findings indicate that RT might provide a novel regimen for patients with locally advanced tumors, especially oligometastatic tumors.</p><p><strong>Conclusions: </strong>Salvage therapy with RT after immunotherapy resistance is the focus of current research. Other strategies, such as multidrug combination therapies, have made preliminary progress in preclinical experiments. Further research on the roles of different RT doses, fractionation regimens, and other treatment sequences in salvage therapy need to be conducted in the future. The optimal site and timing of low-dose radiotherapy are also undetermined, and prospective studies are need to determine the best regimen for optimizing patient treatment.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 2","pages":"591-606"},"PeriodicalIF":4.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921301/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study of the radiologic and pathologic correlations for subsolid lung adenocarcinoma with the application of whole-mount sections (ECTOP1011).","authors":"Ting Ye, Xuxia Shen, Shengping Wang, Haoxuan Wu, Yue Wang, Hong Hu, Yang Zhang, Qingyuan Huang, Zezhou Wang, Yajia Gu, Yuan Li, Haiquan Chen","doi":"10.21037/tlcr-2024-1063","DOIUrl":"10.21037/tlcr-2024-1063","url":null,"abstract":"<p><strong>Background: </strong>The radiologic and pathologic correlations of subsolid lung cancers are unclear. No study has used the whole-mount sections to analyze the correlations. This study aims to clarify the radiologic and pathologic correlations through the use of the whole-mount sections analysis.</p><p><strong>Methods: </strong>Patients with subsolid lung adenocarcinomas receiving segmentectomy or lobectomy were included. The whole-mount sections were made. The same radiologic and pathologic sections were identified. Radiologic and pathologic tumor and solid/invasive sizes were compared. Histologic features in the solid component and ground-glass opacity (GGO) regions were evaluated.</p><p><strong>Results: </strong>There were 102 patients with 20 pure GGO and 82 part-solid tumors analyzed. There was one adenocarcinoma <i>in situ</i>, 32 minimal invasive adenocarcinomas, and 69 invasive adenocarcinomas. For all patients or patients with the matched sections, radiologic tumor diameter was larger than pathologic one (P<0.001; P=0.009), while radiologic solid component diameter was smaller than that of pathologic invasive diameter (P=0.01; P<0.001). The clinical T stage was pathologically upstaged in nearly 50% of patients. For pure GGO tumors, prevalence of lepidic, acinar, and papillary subtypes was 100.0%, 84.2%, and 47.4%, with no micropapillary or solid subtype. For part-solid tumors, in the GGO region, prevalence of lepidic, acinar, papillary, and micropapillary subtypes was 100.0%, 83.3%, 57.1%, and 11.9%, no solid subtype existed. In the solid region, prevalence of lepidic, acinar, papillary, micropapillary, and solid subtypes was 19.0%, 95.2%, 59.5%, 26.2%, and 2.3%.</p><p><strong>Conclusions: </strong>For subsolid lung cancers, the pathologic invasive size was radiologically underestimated. There were acinar/papillary, but no micropapillary subtype in pure GGO tumors. In part-solid tumors, there were micropapillary subtypes in GGO region and micropapillary/solid subtypes in solid region.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 2","pages":"341-352"},"PeriodicalIF":4.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of perioperative carcinoembryonic antigen changes for recurrence in non-small cell lung cancer.","authors":"Hua Sun, Sikai Wu, Zhongxiao Chen, Hao Liu, William C Cho, Pasan Witharana, Minhua Ye, Dehua Ma, Chunguo Wang, Chengchu Zhu, Jianfei Shen","doi":"10.21037/tlcr-24-776","DOIUrl":"10.21037/tlcr-24-776","url":null,"abstract":"<p><strong>Background: </strong>Despite surgical resection, the prognosis for patients with non-small cell lung cancer (NSCLC) remains unsatisfactory. The objective of this study was to investigate the impact of serum carcinoembryonic antigen (CEA) levels on recurrence in patients with NSCLC before and after surgical resection. In addition, for patients with invasive lung adenocarcinoma (IAC), which constitutes the majority of cases, we further explored the effect of pathological subtype on recurrence.</p><p><strong>Methods: </strong>A total of 349 patients were included in the study. The correlation between clinicopathological factors and post-surgery survival outcomes was analyzed. Kaplan-Meier curves were constructed based on the pertinent data and analyzed using the Cox regression model. Recurrence risk curves were plotted according to the time to recurrence for each CEA subgroup and pathological subtype to explore the change in recurrent rate over time in each group.</p><p><strong>Results: </strong>A total of 9 (81.82%) patients in the low preoperative CEA but higher than normal postoperative CEA levels group experienced recurrence, with a median recurrence-free survival (RFS) of only 24 months and a median overall survival (OS) of 57 months. These outcomes demonstrated poorer RFS and OS than those observed in the other three groups. Multivariate analysis of RFS revealed postoperative CEA level (P<0.001), histological type (P=0.01), tumour size (P=0.048), tumor-node-metastasis (TNM) stage (P<0.001) and pN stage (P=0.04) as independent poor prognostic factors. postoperative CEA level (P=0.003), histological type (P=0.02), tumor size (P=0.03), TNM stage (P=0.004) and pN stage (P=0.049) were independent poor prognostic factors for OS. Among the pathological subtypes, patients with Grade 3 (high-grade patterns ≥20%) exhibited a higher risk of recurrence after surgery.</p><p><strong>Conclusions: </strong>Elevated CEA levels in the postoperative period, as well as pathological subtypes of Grade 3, have been identified as risk factors for early recurrence in NSCLC patients after surgery.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 2","pages":"398-407"},"PeriodicalIF":4.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921429/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Light on the horizon for HER2 overexpressing non-small cell lung cancer?","authors":"Kira-Lee Koster, Martin Früh","doi":"10.21037/tlcr-24-859","DOIUrl":"10.21037/tlcr-24-859","url":null,"abstract":"","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 2","pages":"305-309"},"PeriodicalIF":4.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921177/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleeve lobectomy versus lobectomy after neoadjuvant chemo-immunotherapy for non-small cell lung cancer invading the lobar bronchial orifice: a multicenter retrospective cohort study.","authors":"Tianyue Ma, Jun Yi, Yong Ge, Haitang Yang, Jiayi Wang, Shuyuan Li, Ran Ma, Guodong Zhang, Hao Peng, Pingping Song, Feng Yao, Hao Zhang","doi":"10.21037/tlcr-24-925","DOIUrl":"10.21037/tlcr-24-925","url":null,"abstract":"<p><strong>Background: </strong>For non-small cell lung cancer (NSCLC) invading lobar bronchial orifice, sleeve lobectomy is the preferred surgical option. Neoadjuvant chemo-immunotherapy may allow R0 resection with lobectomy. This study aims to compare the long-term outcome of sleeve lobectomy and lobectomy after neoadjuvant chemo-immunotherapy.</p><p><strong>Methods: </strong>We retrospectively screened patients undergoing neoadjuvant chemo-immunotherapy followed by lobectomy or sleeve lobectomy for NSCLC invading lobar bronchial orifice from March 2019 and April 2022. Event-free survival (EFS) was compared between sleeve lobectomy and lobectomy groups in the original cohort and the inverse probability of treatment weighting (IPTW) adjusted cohort. Cox regression was conducted for the potential association between surgical type and EFS.</p><p><strong>Results: </strong>We initially enrolled 248 patients. According to the inclusion criteria, the final analysis included 68 (27.4%) patients: 38 undergoing lobectomy and 30 undergoing sleeve lobectomy. The 2-year EFS was 83.3% versus 60.5% in sleeve and lobotomy groups, respectively [hazard ratio (HR) =0.46, 95% confidence interval (CI): 0.210-1.005; P=0.057]. In Cox regression analysis, improved EFS was associated with pathological complete response (pCR) (HR =0.31, 95% CI: 0.11-0.90; P=0.03) but not surgical types (HR =0.54, 95% CI: 0.22-1.5; P=0.20). In the subgroup analysis including pCR patients (n=31), median EFS was not reached (NR) in either group (P=0.8) before and after IPTW. In the non-pCR subgroup (n=37), median EFS was 21 months (95% CI: 13-NR) in lobectomy group versus not achieved (95% CI: 25-NR) in sleeve lobectomy group (P=0.04) after IPTW.</p><p><strong>Conclusions: </strong>Lobectomy could be feasible for pCR patients and there is survival advantage with sleeve lobectomy in patients failing to achieve pCR after neoadjuvant chemo-immunotherapy.</p>","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 2","pages":"408-421"},"PeriodicalIF":4.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921267/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sunvozertinib: shining light on lung cancer's exon 20 fight.","authors":"Tetsuya Mitsudomi","doi":"10.21037/tlcr-24-907","DOIUrl":"10.21037/tlcr-24-907","url":null,"abstract":"","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":"14 2","pages":"334-340"},"PeriodicalIF":4.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}